Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis

Next Previous
Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenabasum (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Corbus Pharmaceuticals

Most Recent Events

  • 08 Nov 2017 According to a Corbus Pharmaceuticals media release, data from this study was presented at the European Cystic Fibrosis Society ("ECFS") conference in June 2017 and was also recently presented at the North American Cystic Fibrosis Conference ("NACFC").
  • 25 Sep 2017 According to a Corbus Pharmaceuticals media release, data will be presented at the 2017 North American Cystic Fibrosis Conference (NACFC).
  • 09 May 2017 According to a Corbus Pharmaceuticals media release, results from this trial will be presented at the European Cystic Fibrosis (ECFS) conference in June 2017 and the North American Cystic Fibrosis Conference (NACFC) in November 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top